Stifel Financial Corp Has $2.10 Million Holdings in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)

Stifel Financial Corp increased its position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) by 35.8% in the third quarter, according to its most recent 13F filing with the SEC. The firm owned 223,107 shares of the biotechnology company’s stock after purchasing an additional 58,787 shares during the period. Stifel Financial Corp owned about 0.07% of Iovance Biotherapeutics worth $2,095,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. XML Financial LLC lifted its holdings in shares of Iovance Biotherapeutics by 7.4% in the third quarter. XML Financial LLC now owns 14,500 shares of the biotechnology company’s stock valued at $136,000 after purchasing an additional 1,000 shares in the last quarter. Saturna Capital Corp raised its position in Iovance Biotherapeutics by 7.0% during the third quarter. Saturna Capital Corp now owns 20,553 shares of the biotechnology company’s stock valued at $193,000 after buying an additional 1,353 shares during the period. Exchange Traded Concepts LLC lifted its stake in Iovance Biotherapeutics by 11.6% in the 3rd quarter. Exchange Traded Concepts LLC now owns 17,071 shares of the biotechnology company’s stock worth $160,000 after acquiring an additional 1,776 shares in the last quarter. Xponance Inc. boosted its position in Iovance Biotherapeutics by 13.0% during the 2nd quarter. Xponance Inc. now owns 16,279 shares of the biotechnology company’s stock worth $131,000 after acquiring an additional 1,873 shares during the period. Finally, Creative Planning grew its stake in Iovance Biotherapeutics by 2.6% during the 3rd quarter. Creative Planning now owns 73,489 shares of the biotechnology company’s stock valued at $690,000 after acquiring an additional 1,896 shares in the last quarter. Institutional investors and hedge funds own 77.03% of the company’s stock.

Wall Street Analysts Forecast Growth

IOVA has been the subject of a number of research analyst reports. UBS Group initiated coverage on shares of Iovance Biotherapeutics in a research report on Thursday, October 24th. They issued a “buy” rating and a $17.00 price target for the company. HC Wainwright reissued a “buy” rating and set a $32.00 target price on shares of Iovance Biotherapeutics in a research note on Wednesday, November 6th. One analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Iovance Biotherapeutics has a consensus rating of “Moderate Buy” and an average target price of $22.33.

Iovance Biotherapeutics Price Performance

NASDAQ IOVA opened at $7.22 on Friday. Iovance Biotherapeutics, Inc. has a fifty-two week low of $6.70 and a fifty-two week high of $18.33. The stock’s 50-day moving average is $9.50 and its two-hundred day moving average is $9.32. The firm has a market cap of $2.20 billion, a P/E ratio of -4.85 and a beta of 0.55.

Iovance Biotherapeutics (NASDAQ:IOVA) last issued its quarterly earnings data on Thursday, November 7th. The biotechnology company reported ($0.28) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.03. The business had revenue of $58.56 million for the quarter, compared to the consensus estimate of $53.54 million. Iovance Biotherapeutics had a negative return on equity of 58.43% and a negative net margin of 451.25%. During the same period last year, the business earned ($0.46) EPS. On average, equities analysts expect that Iovance Biotherapeutics, Inc. will post -1.23 EPS for the current year.

Insider Transactions at Iovance Biotherapeutics

In other Iovance Biotherapeutics news, Director Ryan D. Maynard sold 50,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $10.06, for a total value of $503,000.00. Following the sale, the director now owns 7,500 shares of the company’s stock, valued at $75,450. This trade represents a 86.96 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. 12.10% of the stock is owned by corporate insiders.

Iovance Biotherapeutics Profile

Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.